tirzepatide compounders FDA Allows Compounded During Shortage Review May 18, 2026: FDA warns

While the tablet is expected to broaden access to GLP-1 therapies, providers increasingly believe the real competitive advantage will come from delivering long-term patient support rather than simply prescribing medication

If it isnt appropriate, they wont prescribe it

Plus, they can cause GI side effects that make it challenging to eat enough and eat well

Short-term thinking leads to common mistakes

In head-to-head analyses, tirzepatide (Zepbound) has produced the largest average weight loss roughly 20% of body weight over 72 weeks in the SURMOUNT-1 trial

Caron Treatment Centers, a long-standing NAATP member, has received national attention for its innovative use of GLP-1 medications such as Zepbound and Ozempic to help reduce cravings for alcohol and illicit drugs